Events．2026.08.21
TWi Biotechnology Brings Global EB Community Together to Discuss Advances in AC-203 and the Future of EB Care
Share:
Global Webinar Connects Patients, Clinicians, Researchers and Industry Around EBS, DEB and the Latest Development of AC-203
TAIPEI, August 21, 2026 – TWi Biotechnology, Inc. (TWi Biotechnology; stock code: 6610.TWO) successfully concluded its global webinar, “Unveiling the Future of Epidermolysis Bullosa Care: Clinical Update and Path Forward on AC-203,” bringing together patients, healthcare professionals, researchers and industry partners from around the world for a shared discussion on the evolving treatment landscape of epidermolysis bullosa (EB).
At the center of the webinar was AC-203, TWi Biotechnology's clinical-stage program for epidermolysis bullosa simplex (EBS). Dr. Yiumo Michael Chan, Senior Consultant to TWi Biotechnology, provided an overview of the disease burden of EBS and took the global audience through the clinical development journey of AC-203 and its previously generated data.
With the global Phase 2/3 clinical trial now in its final stage and unblinding expected in the fourth quarter of 2026, the webinar provided an opportunity for the international EB community to gain a deeper understanding of the development of AC-203 as the program approaches its next important clinical milestone.
The conversation also extended beyond EBS to the challenges faced by patients living with dystrophic epidermolysis bullosa (DEB). TWi Biotechnology had the honor of welcoming Professor Johann Bauer, Professor and Chair of the Department of Dermatology at University Hospital Salzburg and Director of EB House Austria, who provided a clinical perspective on DEB, including chronic wounds, disease burden, and what degree of treatment improvement may be considered clinically meaningful for patients.
Professor Bauer also shared an update on the AC-203 Named Patient Program being conducted in collaboration with EB House Austria. Preliminary observations from individual cases have now been collected and will serve as an important reference for TWi Biotechnology's future clinical development planning.
Bringing these perspectives together, Professor Bauer was joined by Professor Amy S. Paller, Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine, for a panel discussion addressing questions and concerns from participants around the world.
Drawing on their experience in clinical care and drug development, Professor Bauer and Professor Paller discussed the most pressing unmet medical needs across EBS and DEB, the limitations of current standards of care, and what clinically meaningful improvement could look like for patients. The discussion also explored how AC-203, if successfully approved in the future, could potentially change the current treatment approach for EBS, as well as its potential development opportunities in other EB subtypes.
For TWi Biotechnology, the webinar provided a unique opportunity to bring the development of AC-203 into a broader conversation with the people who understand the challenges of EB from different perspectives — patients, physicians, researchers and industry partners — while connecting the progress of its global clinical program with the unmet needs that continue to shape EB care.
Dr. Chen-En Tsai, President and Chief Medical Officer of TWi Biotechnology, commented:
“This global webinar brought together patients, clinical experts, researchers and industry partners to deepen the discussion around the unmet medical needs in EBS and DEB, while providing the international EB community with a clearer understanding of the clinical development direction of AC-203. We will continue advancing the global clinical development of AC-203 and working with international medical experts and patient communities toward our goal of providing EB patients with more convenient and clinically meaningful treatment options.”
For those who were unable to attend the live webinar, please refer to the recording below.
Webinar Q&A
AC-203 is an investigational treatment and is not currently approved or commercially available. It is intended to help manage EBS blisters and skin lesions rather than provide a permanent cure. Availability, access, and pricing, including in India or other countries, cannot be determined at this stage and will depend on the study results and future regulatory approvals.
The panel discussion in Q5 also touched on this question. In brief, AC-203 is currently being developed for EBS and is also being evaluated for expansion into RDEB. Epidermolytic ichthyosis is also associated with pathogenic keratin gene variants, and the potential of AC-203 in other related indications may be considered in the future.
We expect the Part A results of the EBShield study to be unblinded in the fourth quarter of 2026.
This question was covered during the panel discussion and Q&A session. Itching can be an important and challenging symptom in EB, and its management may depend on the individual patient and the underlying cause. Patients and caregivers are encouraged to discuss appropriate treatment options with their EB care team.
These are different therapies developed for different EB populations and treatment goals. As AC-203 is still investigational, a direct comparison cannot be made at this stage.
AC-203 is still under clinical investigation and is not currently commercially available. Access outside the clinical trial will depend on the study results and future regulatory approvals. We will provide further updates as the program progresses.
This question was covered during the panel discussion and Q&A session. There has been significant progress in EB treatment, including gene-based and other targeted approaches. However, there is currently no single cure for all forms of EB, and continued research is needed. In the future, a combination of different treatment approaches may be needed to address the different aspects of EB.
There is currently no approved therapy specifically for EBS. Treatment remains mainly supportive and focuses on symptoms and wound management. Available options may vary by country, so patients should discuss appropriate care with their EB specialist.
The best wound-care approach depends on the type and condition of the wound. As individual wounds and patient needs may differ, this is best discussed with an EB specialist or wound-care team who can recommend an appropriate approach for the individual patient.
This question was covered during the panel discussion and Q&A session. Itching management may depend on the individual patient and the underlying cause. As this question concerns very young children, caregivers are encouraged to discuss appropriate treatment options with their EB care team.
Access to EB treatments varies by country, and some treatments may not currently be available in Uganda. We encourage families to discuss available options with their local EB care team or EB patient organizations, which may be able to provide information on treatment access and support.
Kidney complications have been reported in EB, particularly in more severe forms such as RDEB. Reported complications include glomerulonephritis, IgA nephropathy, amyloidosis, and other renal or urinary tract problems. The risk varies by EB subtype and individual patient, so appropriate monitoring should be discussed with the treating physician.
For more information, please refer to the following publication: pubmed.ncbi.nlm.nih.gov/34123558
Several systemic treatment approaches are currently being investigated for EB, including some oral therapies. However, these are still investigational and further research is needed to establish their safety and efficacy.
As this question relates to another specific treatment, it is outside the scope of this webinar. Patients are encouraged to discuss whether this treatment may be appropriate for them with their EB care team.
Reducing friction and trauma is an important part of EB care. The type and frequency of protective dressings should be individualized based on the patient's skin condition, needs, and activities, ideally with guidance from an EB care team.